This volume emphasizes metastasis/dissemination as im nective tissues, muscle, tumours of neuronal origins and portant processes in cancer growth and progression. teratomas. Previous volumes in this series have emphasized aspects of The broad array of neoplastic diseases, multiple target cancer progression, tumor invasion and tumor metastasis sites, and patterns of metastasis and dissemination underlie and the importance of these processes to the pathophysiol the importance of achieving crucial insights into particular ogy and morbidity of malignant disease. This volume builds neoplasms. An understanding of metastasis and dissemina on these earlier themes and emphasizes metastasis/disse tion in man remains an essential objective for the design of mination in man. Following a review of general patterns of new diagnostic and therapeutic strategies for the therapy of metastatic spread in man, metastasis to, or progression of established metastatic disease and spread accompanying neoplasms in several organ systems are highlighted, includ site-specific tumor progression. ing: the central nervous system, esophageal cancer, the lung, the large intestine, the liver, bone, epithelial neoplasms, Series Editor Volume Editor endocrine cells, pigmented tissues, supporting tissues, con- Hans E. Kaiser Elizier L. Gorelik VII ACKNOWLEDGEMENT Inspiration and encouragement for this wide ranging project on cancer distribution and dissemination from a comparative biological and clinical point of view, was given by my late friend E. H. Krokowski.

This volume, with contributions from the most recognized experts in preventive strategies in breast cancer, presents the accepted as well as the novel ideas that have been introduced for the prevention of breast cancer. There is no single preventive agent that can stop the incidence of breast cancer-the malignant disease most frequently diagnosed in women of all races and nationalities. Furthermore, its incidence around the globe is increasing in industrialized countries. The worldwide incidence of breast cancer has increased 30-40% since the 1970s, reaching an excess of 1,390,000 new cases and a mortality of more than 460,000 cases in 2015. Therefore, what is needed is the development of rational strategies for the prevention of this fatal disease.

The last decade has seen a renaissance of the concept of individualized chemotherapy in oncology, markedly stimulated by the development of new in vitro chemosensitivity assays. The clinical utility of drug response assays has been evaluated in clinical trials and the results suggest that assay-assisted therapy selection may improve survival as well as economic outcomes. This volume comprises the proceedings of the first Symposium of the International Society for Chemosensitivity Testing in Oncology, ISCO-1, held in Homburg/Saar, Germany, in September 2001. The topics include: new in vitro drug-testing methods, tumor chemosensitivity assays, and the clinical relevance of assay-directed therapy.

Jason Micheli, a young father, husband, and pastor, was diagnosed with a bone cancer so rare and deadly that his doctors didn't classify it with one of the normal four stages-they simply called it "stage-serious." As Micheli struggled with despair and faced his own mortality, he resolved that although cancer kills the body, it would not kill his spirit, faith, or sense of humor. Micheli knew that the promise of faith makes hope possible. And approaching cancer as fodder for some bowel-busting humor helps, too. His reflections are not trite. Instead, he writes honestly about being stricken with lethal cancer in the midst of a promising career and raising two young children. He struggles with his commitment to the God who, as he writes, may or may not be doing this to him. Because figuring this out for himself-not to mention explaining it to his congregation and his sons-is so important that theology is now a matter of life and death. This is a funny, no-holds-barred, irreverent-yet-faithful take on the disease that touches every family. Micheli's story teaches us all how to stay human in dehumanizing situations-how to keep living in the face of death.

Biomedical Science Chinese herbal medicine represents complementary or adjunctive therapies that often can improve the efficacy of Western medicine to achieve the pharmacological effects, especially in cancer treatment. However, the combination of herbs with therapeutic drugs can raise potential health risk. Building a bridge between Western medicine and herbal medicines, Active Phytochemicals from Chinese Herbal Medicines: Anti-Cancer Activities and Mechanisms gives you useful information on how integrated medicines can work for cancer therapy. It discusses the therapeutic uses of phytochemicals, adverse effects, and interactions with (Western) cancer drugs. The author takes a unique approach to integrated pharmacology of herbal medicines, examining the development of phytochemicals and their mechanisms of action in the context of the cancers and diseases they are used to treat. He covers biologic action of the active phytochemicals at the molecular, cellular, and organ levels. The book covers the principles of the interaction of phytochemicals and the related drug actions. It also addresses the common pathways affecting cancer development before discussing the phytochemical classes and specific phytochemicals that have been recently reported in journal papers for the management of cancer and other diseases. Highlighting the increasingly important aspects of pharmacology, including health benefit and drawbacks of phytochemicals, the book presents the relevant background of the biochemistry of the cancer. It includes illustrations and tables with adverse reactions that highlight important issues related to phytochemical actions. These features and more make the book a useful reference on phytochemicals obtained from herbal medicines. It blends coverage of fundamental mechanisms of anti-cancer action and the use of phytochemicals to manage cancers and other human diseases, allowing you to explore how herbal medicines can enhance conventional protocols.

The combination of molecular biology, engineering and bioinformatics has revolutionized our understanding of cancer revealing a tight correlation of the molecular characteristics of the primary tumor in terms of gene expression, structural alterations of the genome, epigenetics and mutations with its propensity to metastasize and to respond to therapy. It is not just one or a few genes, it is the complex alteration of the genome that determines cancer development and progression. Future management of cancer patients will therefore rely on thorough molecular analyses of each single case. Through this book, students, researchers and oncologists will obtain a comprehensive picture of what the first ten years of cancer genomics have revealed. Experts in the field describe, cancer by cancer, the progress made and its implications for diagnosis, prognosis and treatment of cancer. The deep impact on the clinics and the challenge for future translational research become evident.

The purpose of Diagnostic and Therapeutic Advances in Pediatric Oncology for the Cancer Treatment and Research Series is to provide an up-to-date summary of how recent advances in cancer research are being applied to the care of children with solid tumors. The interface of cancer research with clinical practice in pediatric oncology has never been more intimate than today. While researchers are identifying oncogenes and tumor suppressor genes and are studying their specific functions, clinicians are using knowledge of oncogenes and tumor suppressor genes for diagnosing cancer in children, for therapeutic decision-making purposes, and for prognostic purposes. The first three chapters in this book describe models for understanding the causes of childhood cancer that were perhaps initially identified by clinicians and that are now being studied and understood by researchers. These chapters will describe research evidence that supports roles for the involvement of normal developmental regulatory genes in childhood oncogenesis, of abnormal immune regulation in childhood oncogenesis, and of heredity in childhood oncogenesis. The next eight chapters are devoted to descriptions of the appli cation of new research developments to clinical practice with reference to the most common forms of solid tumors of childhood outside the central nervous system. The final chapter will describe late effects of childhood cancer and its therapy and the impact research is having on understanding and perhaps preventing these late effects.

Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion. Written in the highly successful Methods in Molecular Biology (TM) format, these detailed chapters include the kind of practical implementation advice that guarantees quality results. Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.

Metastasis is the primary cause of mortality associated with cancer, and tumor genomic heterogeneity is a likely source for the cells that support cancer progression, resistance to therapy, and disease relapse. This book connects cancer metastasis with genomic instability in a comprehensive manner. Section 1 outlines the fundamental mechanisms responsible for these cellular and tissue phenotypes. Section 2 discusses in silico, in vitro, and in vivo models used for the experimental study of these processes. Section 3 reviews emerging themes (ex., microenvironment, mechanotransduction, and immunomodulation), and Section 4 highlights new therapeutic approaches to overcome the unique challenges presented by the heterogeneous and metastatic tumor. This book is intended for undergraduates and postgraduates with an interest in the areas of medicine, oncology, and cancer biology as well as for the content expert searching for thorough reviews of current knowledge in these areas.

Philip Rosenthal, MD, and a panel of leading malaria experts drawn from academia, the military, and international health organizations survey the latest scientific understanding of antimalarial chemotherapy, emphasizing the molecular mechanisms of resistance and the description of important new targets. Their survey covers the current status of malarial and antimalarial chemotherapy, the relevant biology and biochemistry of malaria parasites, the antimalarial drugs currently available, new chemical approaches to chemotherapy, and possible new targets for chemotherapy. Comprehensive and cutting-edge, Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery clearly delineates all the basic and clinical research now addressing one of the world's major unresolved disease problems, work that is now powerfully driving the rapid pace of antimalarial drug discovery today.

This volume reviews our current knowledge concerning can Several chapters discuss the contributions of genetic asp cer growth and progression as it relates to the etiology of ects, metabolism, endocrine-related aspects and nutrition to human cancer. As emphasized in Volumes I-V of this series, cancer progression. Moreover, our current knowledge con neoplastic diseases are multistep maladies. There are many cerning urbanization factors, radiation, therapy-induced causes for the appearance of neoplastic diseases. Earlier neoplasms, environmentally induced neoplasms (e. g., chapters in the series have reviewed molecular and cellular mesotheliomas induced by asbestos) and malignant neo aspects of tumor initiation, promotion and progression to plasms in organ transplant recipients are summarized. the invasive and metastatic phenotype. Contributions to the The impact of AIDS on neoplasm development is re initiation and progression of neoplastic diseases are made by viewed from an epidemiologic perspective that explores mul natural features of the environment and by its contaminants tiple facets of immunity, infectious disease, sexual behavior and by nutritional factors. Neoplastic diseases show a dis and blood transfusion. Other chapters investigate the in tinct relationship to a variety of environmental stimuli and fluence of the host immune response in oncogenesis and the to diseases of a non-neoplastic nature. For example, familial relationship between atherosclerotic plaques and tumors."

James J. Goedert and a team of leading experimental and clinical researchers provide critical, integrating surveys of those viruses, bacteria, and parasites that are now known to play a major role in cancer-work that opens the way toward novel therapeutic targets. The contributors focus on five types of human carcinogenic infection-herpesviruses, retroviruses, papillomaviruses, hepatitis viruses, and H. pylori-and review in depth the associated malignancies, as well as how these new diagnostic and therapeutic technologies may be implemented. Cutting-edge and cross-disciplinary, Infectious Causes of Cancer: Targets for Intervention provides clinical oncologists and infectious disease specialists, as well as clinical researchers, with insightful reviews of cancer induction by infectious diseases and the high promise of closely targeted new therapeutics and vaccines.

Progress in Cell Cycle Research is a new annual series designed to be the source for up-to-date research on this rapidly expanding field. Review articles by international experts examine various aspects of cell division regulation from fundamental perspectives to potential medical applications. Researchers as well as advanced undergraduate and graduate students in cell biology, biochemistry, and molecular biology will benefit from this series.

The present book is a collection of original contributions by specialists in fields related to the more advanced methods presently used or foreseen in the near future for cancer therapy. The use of larger nuclear installations, like particle accelerators and nuclear reactors in oncology is treated in detail, giving an interesting overview of their present and future potential. The aim of the book is to clarify the present state of the art and to encourage new interest in the many fields related to cancer research. The book is particularly suitable for people working in cancer research, but also in other fields, like particle accelerators, nuclear reactors, nuclear medicine and radio-pharmaceutical research. The methods presented in the book are sometimes tentative or not completely established, but clearly reveal the efforts being made to acquire new knowledge for the solution of one of the more serious problems involving the whole of mankind. The book is also required reading for those who want to be informed about the medical research work in large nuclear installations and the most advanced trends in nuclear medicine.

In Leukemia and Lymphoma: Detection of Minimal Residual Disease, hands-on experts describe and discuss the minimal residual disease (MRD) methods they have successfully pioneered for leukemias and lymphomas. They apply reverse transcription PCR (RT-PCR) to acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and acute promyelocytic leukemia (APL). Other PCR methods are used for Non-Hodgkin's Lymphoma and for the monitoring of follicular lymphoma. Additional chapters address the use of real-time quantitative PCR (RQ-PCR), the emergent method of choice, in patients with acute lymphoblastic leukemia (ALL), the evaluation of MRD techniques in clinical trials, and the application of flow cytometry techniques.

Written for residents and practitioners of otolaryngology, medical oncology, radiation oncology, and maxiollofacial surgery, this book provides the reader with a comprehensive, concise discussion of the best evidence available on which to base clinical decisions needed when managing patients with squamous cell carcinomas of the oral cavity, pharynx and larynx. Because of its accessible and practical format, this book is considerably different than other related titles on the market. Formatted with questions at the beginning of each chapter that are then answered with evidence and best practices available for each case, each chapter addresses situations the clinician is likely to face in the diagnostic evaluation and treatment of a patient with cancer of the head and neck. Most clinical decisions in the management of cancers of the head and neck region are based on the results of a few controlled, randomized clinical trial trials (Evidence Level I). However, most decision-making is based on the results of case-control studies (Evidence Level II), descriptive studies, reports of expert committees, or opinions of respected authorities (Evidence Level III). This information is scattered throughout the literature and often comingled with information about other topics. Therefore, there is a need for a publication in which the evidence pertinent to making decisions regarding a particular clinical problem is distilled from the literature and presented in a single concise, clinical, situation-driven source. Cancer of the Oral Cavity, Pharynx and Larynx: Evidence-Based Decision Making is just such a resource.

In June 1998 the Fourth International Workshop on Digital Mammography was held in Nijmegen, The Netherlands, where it was hosted by the department of Radiology of the University Hospital Nijmegen. This series of meetings was initiated at the 1993 SPIE Biomedical Image Processing Conference in San Jose, USA, where a number of sessions were entirely devoted to mammographic image analysis. At very successful subsequent workshops held in York, UK (1994) and Chicago, USA (1996), the scope of the conference was broadened, establishing a platform for presentation and discussion of new developments in digital mammog raphy. Topics that are addressed at these meetings are computer-aided diagnosis, image processing, detector development, system design, observer performance and clinical evaluation. The goal is to bring researchers from universities, breast cancer experts, and engineers together, to exchange information and present new scientific developments in this rapidly evolving field. This book contains all the scientific papers and posters presented at the work shop in Nijmegen. Contributions came from as many as 20 different countries and 190 participants attended the meeting. At a technical exhibit companies demon strated new products and work in progress. Abstracts of all papers were reviewed by members of the scientific committee. Many of the accepted papers had excellent quality, but due to limited space not all of them could be included as full papers in these proceedings. Papers that were rated high by the reviewers are included as long or short papers, others appear as extended abstracts in the last chapter."

Leading researchers and clinicians join forces to explain how malignant melanoma develops from its benign precursor cell type. The authors focus on the molecular mechanisms involved in melanogenesis, in the malignant transformation of melanocytes, and in the further progression of primary melanomas into invasive and metastatic melanomas. They also review recent advances in our understanding of the basic biology of melanocytes and the development, migration, and differentiation of melanoblasts into melanocytes. The book provides an up-to-date understanding of the progressive mechanisms of oncological development in malignant melanoma, a likely model of malignant progress for other types of cancer, and the ongoing development of novel therapeutics.

Target Discovery and Validation: Reviews and Protocols, Volumes 1 and 2 review the most progressive and current methods for drug target discovery and validation. These volumes explore how recent improvement in understanding the molecular mechanisms of human pathology is impacting drug target discovery in the laboratory and in real therapeutics, specifically for cancers and autoimmune disorders.
Volume 1 focuses on novel and innovative techniques, and presents the most up-to-date protocols available for maximizing the likelihood of achieving target-selective inhibition in vivo while minimizing side effects. The profound impact of genomics, proteomics and bioinformatics on target discovery is explored, and specific attention is given to the role of transgenic and knockout animals in functional genomics and target validation. Cancer researchers will find tremendous value in the molecular classification of breast cancers and the review of protocols for tumor antigens and cancer vaccines. The methods and protocols collected here, all reviewed by leading scientists and clinicians, present the practical details necessary for translating the enormous discovery potential of the genome into real therapeutic products.
Volume 2 collects all the practical details required for efficient translation of discovered targets into real pharmaceutical drugs. Specific targets in cancers and autoimmunity are described and the potential of using siRNA's, antisense oligonucleotides and RNA aptimers in patients is reviewed. This volume explores the tremendous impact of the application of genotyping and gene expression profiling on the future of healthcare, and presents cutting-edge protocols to aid inbringing agents against specific targets closer to application in the clinic.
Collectively, these volumes provide a thorough review of the most cutting-edge methods available for each step in drug target identification, validation, and clinical application. For researchers, an understanding of available methods aids in the creation of innovative experiments in the laboratory, and the successful translation of target discovery to real therapeutics.

Knowledge about cancer genetics is rapidly expanding, and has implications for all aspects of cancer research and treatment, including molecular causation, diagnosis, prevention, screening, and treatment.

Additionally, while cancer genetics has traditionally focused on mutational events that have their primary effect within the cancer cell, recently the focus has widened, with evidence of the importance of epigenetic events and of cellular interactions in cancer development. The role of common genetic variation in determining the range of individual susceptibility within the population is increasingly recognized, and is now being widely addressed using information from the Human Genome Project. These new research directions will highlight determinants of cancer that lie outside the cancer cell, suggest new targets for intervention, and inform the design of strategies for prevention in groups at increased risk.

Today, the NCI is putting more and more money into research into the genetics of cancer. The very first of the NCI s stated research priorities is a project called The Cancer Genome Atlas. The Cancer Genome Atlas (TCGA) is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing. The NCI and the NHGRI (National Human Genome Research Institute, where the series editor is employed) have each committed $50 million over three years to the TCGA Pilot Project.

This book proposes cover the latest findings in the genetics of male reproductive cancers; specifically cancers of the prostate and testes. The volume will cover the epidemiology of these cancers; model systems, pathology, molecular genetics, and inherited susceptibility."

This book is a comprehensive review of the current knowledge on cytokines and cancer. Cytokines play a variety of roles in cancer, both as components of pathogenetic mechanisms, as well as agents used in the treatment of certain malignancies. To date, there has not been a book that covers both basic science and translational/clinical research in the field of cytokines in malignancies. This book is written by leading figures in the field of cytokine biology and cytokine therapeutics and is specifically focused on this subject. The book is divided into two parts. The first part is focused on current developments in the basic science field. There is a particular emphasis on novel mechanisms of cytokine actions in malignant cells. The second part deals with translational and clinical research in the field, and many of the authors of these chapters were among the first to introduce several cytokines in the treatment of certain tumors. Collectively, the information provided in this book will be helpful to people in the medical field at several levels, including medical students, interns, residents, clinical and basic science researchers, as well as oncologists in practice.